Clinical trials: Refractory Metastatic Colorectal Cancer

Colorectal Neoplasms, Metastases

Erbitux (Cetuximab) Given Alone to Patients With EGFR-Negative Metastatic Colon or Rectal Cancer That is Refractory to Chemotherapy

• Completed
• Age: 18 years and older
• Phase 2
• Results posted

This is a phase II, multicenter, open-label study of cetuximab in patients with epidermal growth factor receptor (EGFR) negative, metastatic colorectal carcinoma who have progressed after receiving at least one standard…

Conditions

Colorectal Neoplasms, Metastases, Neoplasm

Trial name

NCT00083720

Testing

cetuximab

Where

27 sites in United States, Canada

Volunteers

87 people

Sponsor

Eli Lilly and Company